In the case of viral infection, various viral proteins and genetic components are disseminated in the body. The former viral proteins may be captured by immature dendritic cells (DC) and the latter genetic components may stimulate the antigen-loading DC to maturate via speci®c Toll-like receptors (TLR), leading to the establishment of virus-speci®c cellular immunity; in particular, cytotoxic T lymphocytes (CTL) that control intracellular virions. Polyriboinosinic polyribocytidylic acid [poly(I:C)], which might re¯ect a natural genetic product from a variety of viruses during replication, has recently been identi®ed as one of the critical stimuli for TLR3. Based on these observations, we speculated that stimulation of TLR3 with poly(I:C) might drive the direction of acquired/adaptive immunity to the cellular arm. Indeed, when BALB/c mice were immunized with puri®ed recombinant HIV-1 envelope gp120 or in¯uenza hemagglutinin (HA) protein together with poly(I:C), epitope-speci®c CD8 + class I MHC molecule-restricted CTL were primed from naive CD8 + T cells in vivo. In contrast, when the same proteins were immunized with lipopolysaccharide, a stimulant of TLR4, speci®c CTL were not primed at all. Moreover, we show here that immature DC could present processed antigen from captured puri®ed protein in association with class I MHC molecules in the presence of poly(I:C), but not of LPS. These results indicate that we are able to manipulate the direction of acquired/adaptive effector immune responses using an appropriate stimuli and the ®ndings presented in this paper will offer a new therapeutic strategy using poly(I:C) administration for priming antigen-speci®c CD8 + CTL with puri®ed viral protein in vivo.
Introduction
Our internal defense equipment ®ghts against various pathogens such as bacteria or viruses to protect our bodies and species integrity. Accumulating evidence indicates that the defense system is composed of two parts, innate immunity and acquired/adaptive immunity, which are closely linked in establishing machinery to conquer invading pathogens (1) . The innate alert system is composed of a limited number of germline-encoded receptors without a requirement for genetic rearrangement and those receptors recognize conserved portions of microbial organisms to discriminate non-self from self (1) . Indeed,~10 Toll-like receptors (TLR) (2) ®xed on the sentinels of innate immunity respond to distinct pathogenassociated molecular patterns (PAMP) (3) found on the bacterial cell surface, in their genes or on virus components. For example, bacterial CpG DNA (4), lipopolysaccharide (LPS) of Gram-negative bacteria (5) and peptidoglycan of the bacterial cell wall (6±8) stimulate TLR9, TLR4 and TLR2 respectively. In addition to these bacteria-associated molecular patterns, double-stranded RNA (dsRNA), polyriboinosinic polyribocytidylic acid [poly(I:C)], which might re¯ect a natural product from a variety of viruses during replication, has recently been identi®ed as a critical stimuli for TLR3 (9) .
Viruses can only replicate inside mammalian cells using cellular machinery so that cellular immunity, particularly cytotoxic T lymphocytes (CTL) that recognize virus-derived peptide antigens in association with class I MHC molecules, seems to be the major effectors controlling intracellular virions. In contrast, most bacteria that can proliferate independently outside cells and which are covered with a thick cell wall might be regulated mainly by antibodies and neutrophils expressing Fc receptors for IgG that mediate bacterial opsonization. Thus, it is reasonable to elicit cellular acquired/adaptive immunity in the case of viral infection, whereas antibody-based humoral immunity is feasibly induced in the case of bacterial infection.
Dendritic cells (DC) are located at the interface of innate and acquired/adaptive immunity, and appear to function as connectors. When they are in an immature state like Langerhans cells in the skin, they might sample and uptake various antigenic molecules around them. Upon encountering a pathogen-derived component expressing PAMP, they differentiate into the matured phenotype that express both processed antigenic epitope in conjunction with MHC and costimulation molecules to activate acquired/adaptive immunity by priming naive antigen-speci®c T cells (10) . Therefore, these matured DC seem to represent key commands for driving the direction of acquired/adaptive immune responses. Thus, some PAMP stimuli might drive the appropriate directions of acquired/adaptive effector immunity via TLR on DC.
In the present study, we examined whether PAMP stimuli via TLR3 by poly(I:C) turn the direction of acquired/adaptive immunity to the cellular arm when using soluble viral proteins that must be dispersed in the case of viral intrusion. We used puri®ed recombinant HIV-1 envelope gp120 protein and in¯uenza hemagglutinin (HA) protein as the known antigens. As expected, when BALB/c mice were immunized with these virus-derived proteins together with poly(I:C), epitope-speci®c CD8 + class I MHC molecule-restricted CTL were primed, whereas when the same proteins were immunized with LPS, a stimulant of TLR4, speci®c CTL were not primed. In addition, we show here that immature DC (iDC) could present processed antigen derived from puri®ed protein in association with class I MHC molecules in the presence of poly(I:C), but not of LPS. These results indicate that the direction of acquired/adaptive effector immune responses could be manipulated using appropriate PAMP and suggest that poly(I:C) could be an attractive adjuvant for immunotherapy to drive cellular immune responses.
Methods

Mice
Female BALB/c (H-2 d ) mice were purchased from Charles River (Tokyo, Japan). Mice used in this study were at 6±12 weeks of age and maintained in a speci®c pathogen-free environment. All experiments were performed according to the guidelines of the NIH Guide for the Care and Use of Laboratory Animals.
Synthetic peptides
Epitope peptides for HIV-1 envelope-speci®c CTL, P18IIIB (315±329, RIQRGPGRAFVTIGK) (11), for determining HIV-1 V3-speci®c antibodies of IIIB isolate by ELISA, Rp135 (NNTRKSIRIQRGPGRAFVTIGKIGC) (12) , and for in¯uenza HA-speci®c CTL, the HA of in¯uenza A/PR/8/34 (H1N1) (518± 528, IYSTVASSLVL) (13), were synthesized using an Applied Biosystems model 430A peptide synthesizer (Foster City, CA). Synthetic peptides were further puri®ed by gel ®ltration on Biogel P-4 and analyzed by HPLC on a C 18 reversed-phase column. Peptide fractions containing >90% of the desired product were used for the experiments.
Reagents and antibodies
Poly(I:C) and LPS (from Escherichia coli) were purchased from Sigma (St Louis, MO). Recombinant HIV-1 gp120 protein of IIIB isolate was provided by the National Institute of Health (Bethesda, MD) or purchased from Immuno Diagnostics (Woburn, MA). Puri®ed in¯uenza HA protein was provided by Nissin Sei-yu (Yokohama, Japan). The purity of the proteins used in this study was >95%. The endotoxin content of all reagents was tested by the Limulus amebocyte lysate assay (Seikagaku, Tokyo, Japan) and the level was <20 pg/ml. The following mAb were used for depleting the T cell subset: anti-CD4 mAb (RL172.4; rat IgM) (14) and anti-CD8 mAb (3.115; rat IgM) (15) .
Transfectants BALB/c.3T3 (H-2 d ) ®broblast transfectants expressing HIV-1 gp160 of IIIB isolate and control transfectants with only the selectable marker genes (Neo) were derived as described previously (11, 16 (18) were used to determine class I MHC restriction of the generated CTL. All cells were maintained in complete T cell medium (CTM) (19) , consisting of RPMI 1640 medium supplemented with 10% heat-inactivated FCS, 5 mM HEPES buffer solution (Gibco/BRL, Santa Clara, CA), 100 U/ml penicillin (Gibco/BRL), 100 mg/ml streptomycin (Gibco/BRL), 2 mM L-glutamine (Gibco/BRL), 2 mM sodium pyruvate (Gibco/BRL), 2 mM non-essential amino acid (Gibco/BRL), 2 mM modi®ed vitamins (Dainippon Pharmaceutical, Tokyo, Japan) and 2 mM 2-mercaptoethanol (Sigma).
Generation of CTL lines
Spleen cells (5 Q 10 6 ) from BALB/c mice previously immunized with 1 Q 10 7 p.f.u. of vSC25 (recombinant vaccinia virus expressing the HIV-1 envelope glycoprotein gp160 of the IIIB isolate) (20) were re-stimulated in vitro with 1 Q 10 5 mitomycin C (MMC)-treated 15-12 cells in 24-well plates containing 1.5 ml of CTM and 10% Rat T-STIM (Collaborative Biomedical Products, Bedford, MA). To establish CTL lines, the generated CTL were maintained by bi-weekly stimulation with MMC-treated 15-12 cells and named the LINE-IIIB cells.
Measurement of cytokine production
IL-12-p40, IL-10, IFN-g and IL-4 levels in mice serum samples were measured using speci®c ELISA kits (BioSource International, Camarillo, CA).
Immunization and CTL generation
Female BALB/c mice were immunized either i.p. or s.c. in the base of tail with 1 mg recombinant gp120 protein with or without either 100 mg poly(I:C) or 100 mg LPS. Four to 12 weeks later, 5 Q 10 6 immune spleen cells were re-stimulated in vitro for 6 days with MMC-treated 15-12 cells in CTM and 10% Rat T-STIM. Similarly, 10 mg recombinant in¯uenza HA (H1N1) protein was immunized with or without either 100 mg poly(I:C) or 100 mg LPS to prime HA-speci®c CTL.
CTL assay
After culture for 6 days, cytolytic activity of the re-stimulated spleen cells was measured as previously described (21) using a standard 51 Cr-release assay with various 51 Cr-labeled targets. In brief, the generated cells were harvested and mixed with various 51 Cr-labeled target cells in 96-well, Ubottomed culture plates in RPMI 1640 containing 10% FCS at various E:T ratios. After incubation for 4±6 h at 37°C, the plates were centrifuged for 10 min at 330 g and cell-free supernatants were collected to measure radioactivity using a Packard Auto-Gamma 5650 counter (Hewlett-Packard Japan, Tokyo, Japan). Maximum release was determined from the supernatant of cells that had been lysed with 5% Triton X-100 and spontaneous release was determined from target cells incubated without added effector cells. The percent speci®c lysis was calculated as 100 Q (experimental release ± spontaneous release)/(maximum release ± spontaneous release). SEM values of triplicate cultures were always <5% of the mean. Each experiment was performed at least 3 times.
Measurement of antigen-speci®c antibodies by ELISA
Serum samples were obtained 3±4 weeks after the immunization. The concentrations of V3 peptide-speci®c IgG1 and IgG2a antibodies in the sera was determined using sandwich ELISA assays. In brief, microtiter plates (cat. no. 439454; Nalge Nunc International, Tokyo, Japan) were coated overnight at 4°C with 100 ml/well of 10 mg/ml Rp135 peptide in 0.1 M sodium carbonate buffer (pH 9.6). After blocking with 1% BSA in PBS, serum samples were added to the plate and incubated for 1 h at 37°C. Thereafter, the plates were washed and horseradish peroxidase-conjugated rabbit anti-mouse IgG1 (A85-1) or IgG2a (R2-40) (2 mg/ml; Zymed, San Francisco, CA) was added to each well and incubated for 1 h at 37°C. Color was developed using tetramethylbenzidine and the optical density was measured at 450 nm using a microplate reader (model 3550; Bio-Rad, Hercules, CA).
Generation of DC and their sensitization with gp120 protein for CTL recognition DC were generated from bone marrow precursors as described by Inaba et al. (22) with slight modi®cations. Brie¯y, bone marrow cells¯ushed out of the femurs from BALB/c mice were separated by centrifugation and red blood cells were lysed. After washing twice, cells were plated at a density of 5 Q 10 5 cells/well in 1 ml of CTM containing 1000 U/ml of recombinant murine granulocyte macrophage colony stimulating factor (GM-CSF; Kirin Brewery, Gunma, Japan) in 24-well plates and cultured at 37°C in 5% CO 2 . On days 2 and 4, non-adherent cells were removed and replaced with fresh medium containing the same amount of GM-CSF. On day 5, non-adherent cells were harvested and used for CTL assays. Flow cytometry analysis revealed that >80% of the harvested cells were CD11c + DC. These were further incubated at a density of 2 Q 10 5 cells in 48-well plates for 24 h in the presence of 5 mg gp120 protein alone, or with either 100 mg/ml poly(I:C) or the same amount of LPS. After the incubation, these treated DC were harvested and used as targets for CTL assays or as stimulators for primed T cells.
Statistical analysis
Data are presented as mean values T SD. Data were statistically analyzed by Student's t-test. A value of P < 0.05 was considered as the level of signi®cance.
Results
Kinetics of systemic and local cytokine production in mice after poly(I:C) or LPS injection
It has recently been demonstrated that poly(I:C) can activate innate immunity via TLR3 and stimulate IL-12 production in vivo using the C57BL/6 (H-2 b ) mouse strain when 50 mg poly(I:C) was inoculated i.p. (9) . In order to con®rm this phenomenon in different haplotype mice, we injected BALB/c (H-2 d ) mice with 0, 10, 30 or 100 mg poly(I:C), and pursued the amount of IL-12 in the sera by ELISA 2, 6 and 8 h after i.p. or s.c. injection. Figure 1 (A, left panel) shows that the serum IL-12 level increased in a dose-dependent manner and at 100 mg poly(I:C) i.p., >10 ng/ml of IL-12 was detected in the sera 2 h later. This amount decreased thereafter over time. Because these observations showed that poly(I:C) affected systemic immune responses in vivo, we next examined the local effects of poly(I:C) when injected s.c. IL-12 elevation was also observed in sera from the tail vein of BALB/c mice inoculated with 100 mg poly(I:C) in the base of the tail (Fig. 1A, right  panel) . In contrast, IL-12 was undetectable in the sera of control mice injected both i.p. and s.c. with either PBS or the same dose of poly(A:U), which cannot activate the TLR3 pathway (9) (data not shown). We then injected BALB/c mice either i.p. or s.c. with the same amount of LPS that would stimulate innate sentinels via TLR4 as internal controls. Figure 1 (B, left and right panel) shows that a little more IL-12 was detected in the sera of mice inoculated with 100 mg LPS both i.p. and s.c. The mice appeared unaffected even when injected with the highest dose (100 mg) of poly(I:C) and LPS. Thus, we decided to use 100 mg poly(I:C) and LPS for further experiments.
Because IL-12 production by innate immunity re¯ects the activation of T h 1-type cellular immune responses in acquired immunity (23, 24) , we also examined serum IL-10 production, which might correlate with T h 2-type humoral immune responses by inhibiting IL-12 production in vivo (25, 26) . About 2000 pg/ml of IL-10 could be measured in the sera of LPSinoculated mice immunized both i.p. and s.c., although very little IL-10 was detected in the sera of mice injected with poly(I:C) (Fig. 1C) . Moreover, we detected IFN-g (Fig. 1D ) in the sera of mice injected with 100 mg poly(I:C) and LPS. However, we could not observe any measurable amount of IL-4 in the sera of poly(I:C)-injected mice although a small amount of IL-4 was detected in sera from mice injected with LPS (Fig. 1E ). Thus, in vivo i.p. and s.c. injections of poly(I:C) might help to dominantly generate T h 1-type acquired immunity, whereas LPS might help to elicit both T h 1-and T h 2-type immunity.
Induction of HIV-1 gp120-speci®c killer cells by immunization with recombinant gp120 protein and poly(I:C)
The above ®ndings suggest that the local presence of viral dsRNA such as poly(I:C) may help to induce virus-speci®c T h 1-type cellular immune responses. Therefore, to generate killer cells, recombinant puri®ed HIV-1 gp120 envelope protein was co-administered with 100 mg poly(I:C) into BALB/c mice via either the i.p. or s.c. route. After 4 weeks, immune spleen cells were re-stimulated in vitro with MMC-treated syngeneic BALB/c.3T3 ®broblasts expressing the HIV-1 gp160 envelope gene of IIIB isolate and cytotoxicities were measured using a standard 51 Cr -release assay. We found that gp120-speci®c killer cells were generated from mice immunized s.c. with 1 mg gp120 protein and 100 mg poly(I:C), whereas no cytotoxicity was observed in mice immunized i.p. with the same immunogens (Fig. 2A) . These results indicate that s.c. inoculation was the optimal route for the induction of killer cells. Thus, we administered 100 mg poly(I:C) together with various amounts of gp120 protein s.c. to determine whether envelope-speci®c CTL were primed in vivo. As demonstrated in Fig. 2(B) , HIV-1 envelope-speci®c cytotoxic activity was generated in a dose-dependent manner when immune spleen cells of BALB/c mice were re-stimulated in vitro with MMCtreated 15-12 cells. The generated killer cells obtained by s.c. immunization with 100 mg poly(I:C) together with 1 mg recombinant gp120 protein speci®cally killed ®broblast targets that either expressed whole envelope protein or pulsed with a synthetic epitope peptide (P18IIIB: RIQRGPGRAFVTIGK) (Fig. 2C) . In addition, when mice were immunized with 1 mg gp120 and various amounts of poly(I:C), speci®c cytotoxic activity was observed only in those injected with 100 mg poly(I:C) (Fig. 2D) . Thus, 1 mg recombinant gp120 protein and 100 mg poly(I:C) were suf®cient for priming virusspeci®c CTL in vivo. In contrast, we could not detect any speci®c cytotoxic activity when BALB/c mice were injected with 1 mg gp120 and either PBS (Fig. 2E ) or 100 mg LPS (Fig. 2F) , or a lower dose of LPS (data not shown). These results indicate that virus-speci®c CTL could be primed with poly(I:C) via TLR3 stimulation, but not with LPS via TLR4 using viral proteins for s.c. immunization, and thus suggest that the feasibility of vaccination to prime virus-speci®c CTL by immunization with recombinant viral proteins and poly(I:C).
Characterization of the induced killer cells
Because immunization with exogenous antigen generally primes MHC class II-restricted CD4 + T cells, we examined the phenotype and MHC restriction of the generated killer cells. When the killer cells were treated with anti-CD4 mAb plus complement or complement alone, their cytolytic activity was almost unchanged. However, treatment with anti-CD8 mAb plus complement led to a complete reduction in their cytotoxic activity (Fig. 3) . To determine the class I MHC molecule restriction, we used the L cell-based transfectants, T4.8.3, T1. 
Induction of in¯uenza HA-speci®c CTL by immunization with recombinant HA protein and poly(I:C)
To generalize the observation that virus-speci®c CTL could be primed by immunization with viral protein and poly(I:C), we used puri®ed in¯uenza HA (H1N1) protein as the antigen. As demonstrated in Fig. 4(A) , an immunodominant epitope of HA, HA 518±528 (IYSTVASSLVL), speci®c killer cells were generated when spleen cells of BALB/c mice immunized s.c. with 10 mg HA protein and 100 mg poly(I:C) were re-stimulated in vitro for 6 days with syngeneic ®broblasts pre-sensitized with HA 518±528 peptide. In contrast, speci®c cytolytic activity was undetectable when the mice were immunized with 10 mg HA protein with either PBS (Fig. 4B) or with 100 mg LPS (Fig. 4C) . We con®rmed that the generated killer cells were CD8 + K drestricted conventional CTL (data not shown). Therefore, both HIV-1 gp120-speci®c CTL and in¯uenza HA-speci®c CTL could be primed by s.c. immunization with puri®ed viral protein and poly(I:C).
Analysis of antibodies in the sera of mice immunized with recombinant gp120 protein and adjuvant
We then examined the amount and type of gp120-speci®c antibodies in mice sera. As speculated from the pattern of serum cytokine production, predominant production of HIV-1 V3 (Rp135)-speci®c IgG2a (T h 1-type) antibodies was measured in the sera of mice immunized s.c. with gp120 and poly(I:C) (Fig. 5A) . In contrast, V3-speci®c IgG1 (T h 2-type) antibodies were dominantly observed when mice were immunized s.c. with 1 mg gp120 and 100 mg LPS (Fig. 5B) . Therefore, we con®rmed that T h 1-type systemic responses proceeded in the mice injected with poly(I:C), whereas T h 2-type responses were induced by inoculation with LPS in vivo.
Sensitization of DC with recombinant gp120 protein in the presence of poly(I:C)
Finally, to analyze the mechanism of these phenomena, we examined whether immature bone marrow-derived DC (BM-DC) could uptake gp120 protein in the presence of poly(I:C) and present the processed peptide antigen to CTL in vitro. Based on the previous observations (22, 27) , immature BM-DC were incubated with 5 mg gp120 protein with or without 100 mg/ Fig. 5 . Type of HIV-1 V3-speci®c antibodies produced in the sera of mice immunized with recombinant gp120 protein and poly(I:C). Female BALB/c mice were immunized s.c. with 100 ml PBS, 100 mg poly(I:C), 1 mg gp120 protein, gp120 protein and poly(I:C) or gp120 protein and 100 mg LPS. Four weeks after the immunization, HIV-1 V3 (Rp135)-speci®c IgG1 and IgG2a levels were determined by ELISA. (A) Predominant production of V3-speci®c IgG2a (T h 1-type) antibodies was observed in the sera of mice immunized s.c. with 1 mg gp120 and 100 mg poly(I:C). (B) V3-speci®c IgG1 (T h 2-type) antibody production was dominantly observed when mice were immunized s.c. with 1 mg gp120 and 100 mg LPS. Data are representative of at least three independent experiments. Error bars indicate the SD. Statistical analysis was performed using paired Student's t-test between immunization of recombinant gp120 protein with poly(I:C) and LPS; V3-speci®c IgG2a (*P = 0.0099) and V3-speci®c IgG1 (**P = 0.015). Fig. 6 . Sensitization of DC with recombinant gp120 protein in the presence of poly(I:C). (A) Five-day-cultured BM-DC were incubated with PBS, 100 mg/ml poly(I:C), 5 mg gp120 protein, gp120 protein and poly(I:C) or gp120 protein and 100 mg/ml LPS for 24 h in a 48-well¯at-bottomed plate. As a positive control, BM-DC were pulsed with 1 mM P18IIIB. After being labeled with 51 Cr and washed 3 times, the treated DC were co-cultured with P18IIIB-speci®c CTL (LINE-IIIB) to perform 4-h cytotoxic assays at various E:T ratios. (B) IL-12 and IL-10 production in the supernatant of 5-day-cultured BM-DC incubated with either 100 mg/ml poly(I:C) or 100 mg/ml LPS. The amount of cytokine production was measured with each speci®c ELISA kit. (C) Female BALB/c mice were immunized s.c. in the base of the tail with 1 mg gp120 protein and 100 mg poly(I:C). After 4 weeks, immune spleen cells were re-stimulated in vitro with the following MMC-treated DC and Rat T-STIM: DC alone (open circle); DC incubated with 5 mg gp120 protein (open square); DC with 5 mg gp120 protein and 100 mg/ml poly(I:C) (®lled triangle); and DC with 5 mg gp120 protein and 100 mg/ml LPS (®lled square). After 6 days of culture, cytotoxic activities were tested against 51 Cr-labeled P18IIIB-pulsed BALB/c.3T3 ®broblasts (Neo) as targets. Data are representative of at least three independent experiments. ml of poly(I:C) or the same amount of LPS for 24 h at 37°C. After extensive washing to remove free antigenic protein and reagent, the cells were used as targets for 4-h CTL assay. As demonstrated in Fig. 6(A) , BM-DC pulsed with gp120 protein and poly(I:C) were recognized and killed by a P18IIIB-speci®c CTL line (LINE-IIIB), whereas those pulsed with gp120 protein alone or with LPS were not lysed. In contrast, when BM-DC were pulsed with the same amount of gp120 protein and poly(A:U), they could not be lysed by LINE-IIIB (data not shown). These results indicate that the epitope peptide from gp120 protein was processed and presented to the MHC class I molecules in the presence of poly(I:C).
We also examined the cytokine productions in the supernatant of those cultured BM-DC. Although both IL-12 and IL-10 production was detected in the supernatant after stimulation with LPS, IL-12, but not IL-10, could be measured in the poly(I:C)-stimulated supernatant (Fig. 6B) . Moreover, the BM-DC sensitized with gp120 and poly(I:C) could speci®cally stimulate vSC25-primed splenic T cells, although BM-DC treated with gp120 and LPS or with gp120 alone did not stimulate the primed T cells (Fig. 6C) . These results suggest that recombinant gp120 protein captured by iDC such as Langerhans cells in the skin was processed and presented in association with class I MHC molecules of these DC via maturation via poly(I:C), and that matured antigen-bearing DC might prime epitope-speci®c CD8 + CTL in vivo.
Discussion
The present study demonstrates that a single administration of viral protein such as HIV-1 gp120 or in¯uenza HA could prime virus epitope-speci®c CD8 + class I MHC molecule-restricted conventional CTL when inoculated together with poly(I:C), an IFN inducer (28) that is sometimes used in models of viral infection, but not with LPS, re¯ecting the PAMP of the viral product recognized by TLR3 and the bacterial component by TLR4 respectively. It is reasonable to elicit cellular acquired/ adaptive immunity, in particular virus-speci®c CD8 + CTL which might control intracellular virions, by disseminated viral proteins and genetic products after virus intrusion. The former viral proteins might be captured by iDC such as Langerhans cells and the latter virus-derived genetic products such as poly(I:C) might drive the direction of iDC with captured antigen towards the T h 1 route for priming naive CD8 + T cells into viral protein-speci®c CTL. However, if LPS-bearing bacterial infection was overlapped at the same time, the direction of antigenloaded DC might be shifted to T h 2 and CTL generation would be disturbed. This would prolong the viral infection by inhibiting CTL induction via wrong manipulation of the DC with viral protein by LPS. However, it has recently been reported that bacteria-derived CpG DNA, PAMP for TLR9 recognition (4), might help to elicit antigen-speci®c CTL (29, 30) . Therefore, in contrast to LPS, some bacterial products may help to clear the virus-infected cells in vivo by turning the direction of T cell activation to T h 1 route.
We have previously reported that DC are essential for priming CD8 + CTL and we could generate CTL by i.v. inoculation with epitope peptide-pulsed irradiated splenic DC (31) . In that study, we noticed that the ef®cacy of CTLpriming by splenic DC was up to the conditions of peptideloaded DC. In general, LPS is useful for the maturation of DC (32) , which then secrete cytokines such as IL-12, tumor necrosis factor-a, IL-6 or IL-10. Actually it has been shown that i.v. immunization of epitope peptide-pulsed spleen cells activated in vitro by LPS could induce speci®c CTL (33) . However, Kelleher and Beverley have recently reported that modulation of DC by LPS could not stimulate antigen-speci®c CTL from naive polyclonal CD8 + T cells in vitro (34) . Our results similarly indicated that the maturation of antigen-captured DC by LPS would not help to prime speci®c CTL from naive splenic T cells in vivo. Moreover, as we will discuss below, LPS appeared to inhibit the MHC class I presentation pathway for captured intact viral protein via IL-10 production. Conversely, poly(I:C)-stimulated iDC seemed to ef®ciently proceed crosspresentation of captured viral protein probably by predominant secretion of IL-12 at the very early stage and low production of IL-10, as has been reported recently (35, 36) . Collectively, externally added IL-12 and anti-IL-10 may mimic the poly(I:C)-mediated environment where naive CD8 + T cells might be primed effectively.
Thus, the pattern of cytokine production by DC via TLR ligand such as LPS or poly(I:C) appears to be critical for determining the direction of acquired/adaptive immune responses. However, as has shown in Fig. 1 , although the pattern of cytokine production observed after poly(I:C) administration in the base of the tail (s.c.) was similar to that systemically produced by i.p. inoculation, antigen-speci®c CTL could be primed in vivo only when mice were s.c. immunized with gp120 protein and poly(I:C). These results are consistent with those of others who reported that immunization with antigens at`the base of the tail' (s.c.) for CTL priming (37± 39). This notion of s.c. inoculation is also consistent with our previous observation using gp120 protein and immunostimulating complexes, consisting of materials derived from plants for the induction of gp120-speci®c CTL (40) . Unfortunately, none of the reports have precisely analyzed and compared the routes of immunization for CTL induction. The iDC of the skin and mucosa, Langerhans cells, have been implicated as the ®rst targets for HIV after sexual contact (41, 42) , and they constantly sample antigenic molecules from their environment until activation by a maturation signal. After maturation, such iDC located in non-lymphoid surface areas migrate to secondary lymphoid tissue, where they present processed antigen to T cells (43) . Thus, our current results suggest that poly(I:C)/TLR3 signaling might activate such antigen-loaded iDC existing in the s.c. tissues, that allows them to crosspresent exogenous antigens to prime CD8 + CTL. Taken together, s.c. immunization seems to be a better route for priming CD8 + CTL than the i.p. route. However, more precise analysis is required to prove those mechanisms.
Our current ®ndings showed that antigenic peptides derived from puri®ed HIV-1 gp120 protein could be crosspresented in association with class I MHC molecules by BM-DC in vitro in the presence of poly(I:C), but not of LPS. It is generally assumed that exogenously captured antigenic proteins are delivered to acidic endosomes, processed and ef®ciently presented on MHC class II molecules by professional antigen-presenting cells (44, 45) . Thus, there must be other unknown pathways that will be opened to cross-present those internally processed antigens on class I MHC molecules instead of class II MHC when protein-loaded iDC are stimulated by special substance like poly(I:C) via TLR. Indeed, consistent with our observation, very recently it has been shown that such cross-presentation of captured soluble proteins to class I MHC could be generated in BM-DC via maturation with a subset of TLR ligand such as immunostimulatory CpG DNA for TLR9 and poly(I:C) for TLR3 (46) . Since the CpG DNA fail to develop CTL response in TAP-de®cient BM-DC (47), the poly(I:C)-mediated TLR-dependent cross-presentation of captured cytosolic antigens also seems to require TAP and proteasomal processing, but not endosomal acidi®-cation. Moreover, the fact that TAP function could be inhibited by 48) indicates that the low production of IL-10 maintained by both in vivo and in vitro treatment of iDC by poly(I:C) might activate the TAP-dependent pathway that enables it to cross-present processed antigen to class I MHC molecules. Further investigation will be required to examine the actual effect of poly(I:C)/TLR3 signaling on such crosspresentation and cross-priming.
In the case of certain viral infections, there must be a large number of iDC that have already captured disseminated viral protein fragments in vivo. The present study indicates the possibility that we could manipulate the direction of such iDC for priming neighboring CD8 + T cells to generate antigenspeci®c CTL effectors by poly(I:C). The ®ndings presented here will offer a new therapeutic strategy using poly(I:C) administration to prime or activate antigen-speci®c CD8 + CTL both in vitro and in vivo.
